Leading kidney disease care management company Monogram Health announced that it has raised $7 million in funding

Leading kidney disease care management company Monogram Health announced that it has raised $7 million in funding through the closing of a Series A-1 financing round. This round of funding was co-led by Frist Cressey Ventures and Norwest Venture Partners.

This funding represents another significant milestone for Monogram as the company is continuing to grow, increase health plan partnerships, and manage the care of vulnerable patients with kidney disease through in-home engagement and increased interaction during this time of heightened isolation brought forth by the COVID-19 pandemic.

Monogram is currently operating its kidney disease care management programs for thousands of patients across the U.S., including Humana Medicare Advantage and Commercial plan members in Louisiana and Mississippi. And the company partners with health plans to collaborate with nephrologists and ensure high-quality patient care is delivered cost-effectively.

And Monogram’s care management team of nurses, social workers, nephrologists, and geriatricians develop strong and lasting relationships with patients through in-person visits to their homes, inclusive of family members and community support as a means of improving overall health outcomes. And through these regular visits, Monogram’s specialized care teams monitor and manage patients’ kidney care delivery like appropriate medication compliance as well as transitions to and adherence with renal replacement, palliative care, and other evidence-based treatment modalities.

And the funding comes at a time as the Centers for Medicare and Medicaid Services is increasing its attention and focus on the cost and quality of kidney care for its Medicare beneficiaries. And through the 21st Century Cures Act, Medicare beneficiaries with end stage renal disease will have the option during the Annual Election Period (AEP) later this year to enroll in 2021 Medicare Advantage plans administered by private health insurers to provide coverage for their care needs.

Key Quotes:

“We pride ourselves on working with innovative companies that are truly transforming the delivery of healthcare, and we share in Monogram’s vision of making kidney care more accessible to more people, lowering the cost of care, and at the same time improving their quality of life and health outcomes. In light of the COVID-19 pandemic, the need for high-quality, in-home kidney health services are only growing, and Monogram is at the forefront of this shift to home-based care management and delivery.”

“The COVID-19 pandemic has put a spotlight on the home as a safe healthcare setting for dialysis and other kidney-related care. Monogram’s solution empowers the vulnerable patients with renal disease to be seen in the comfort and safety of their own homes and to choose treatment modalities that are home-based, rather than clinic-based. This innovative approach to managing kidney care delivery will help improve health outcomes for a population that drastically needs and deserves better care.”